RxDoctor Payments Data

Michael Mason, PA

Physician Assistant · Salisbury, MDNPI 1487926549

Payments from drug & device makers

$2,859in general payments, 2019–2025

Across 107 payments — averaging $26.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Madrigal Pharmaceuticals$301
  • Sanofi$157
  • Phathom Pharmaceuticals, Inc.$149
  • Ferring Pharmaceuticals Inc.$141
  • Gilead$135
  • plus $932 from 14 others

What the payments were for

  • Food & beverage$2,859100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,859 in reported general payments places this provider in the 85th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$55,998
Medicare patients
470
Services billed
709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase22$79,942
LinzessLinaclotide22$18,488
VoqueznaVonoprazan Fumarate18$11,878
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates91$5,555
Pantoprazole Sodium171$2,471
Esomeprazole Magnesium67$2,172
CholestyramineCholestyramine (With Sugar)27$2,153
Dexlansoprazole DrDexlansoprazole11$1,950
Omeprazole118$1,094
Famotidine134$874
Lactulose14$708
Sucralfate17$690
Dicyclomine Hcl45$675
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl19$261
Spironolactone14$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,044$98,43044 claims
Phathom Pharmaceuticals, Inc.Voquezna$149$11,87818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →